#Sweden #Epigenica #EpiFinder #GenomePro #Solna

Epigenica AB Launches EpiFinder™ GenomePro

Epigenica AB, a prominent innovator in epigenomic research, has announced the release of its latest product, EpiFinder™ GenomePro. This cutting-edge tool enhances the ability of researchers to explore the complex landscape of post-translational modifications of histones (hPTM) and DNA methylation, achieving both high throughput and cost-effectiveness while maintaining exceptional data quality.

What is EpiFinder™ GenomePro?

EpiFinder™ GenomePro is the next-generation version of the original EpiFinder™ Genome. It boasts optimized reagents and streamlined protocols that allow simultaneous analysis of 24 samples. This innovative platform generates robust quantitative data for 192 genome-wide sequencing profiles through chromatin immunoprecipitation sequencing (ChIP-Seq) across multiple hPTM and DNA methylation, leveraging minimal sample volumes.

One of the standout features of EpiFinder™ GenomePro is its capacity to reduce the cost per sample significantly, making large-scale studies more accessible than ever before.

Flexible Design for Customized Research

The platform is ingeniously designed to allow researchers to select their preferred hPTMs with or without DNA methylation. Coupled with an open-source data analysis pipeline, EpiFinder™ GenomePro ensures a streamlined approach to data analysis, with unparalleled transparency and reproducibility.

According to Mohamad Takwa, CEO of Epigenica AB, “With EpiFinder™ GenomePro, we are setting a new standard in epigenomic research. Our vision is to provide a platform that delivers invaluable insights, enabling scientists to tackle complex biological questions with unprecedented scale and accuracy.”

Advancing Research Across Therapeutic Areas

EpiFinder™ GenomePro stands to propel research in various therapeutic fields. It aids in decoding the epigenetic mechanisms that drive disease onset and progression while predicting patient responses to treatments. By providing high-resolution and broadly applicable epigenomic data, the platform empowers scientists to discover new biomarkers, map complex pathological processes, and generate critical insights for developing targeted precision therapies.

User-Friendly for All Levels of Researchers

The EpiFinder™ GenomePro kit represents an excellent method for labs that may have limited experience with ChIP-Seq or similar techniques to obtain high-quality ChIP-Seq data without significant time investments. Björn Reinius, an associate professor at the Karolinska Institute whose research focuses on gene dosage compensation, articulates that, “With minimal optimization, the protocol allows users to generate quantitative ChIP-Seq libraries and perform preliminary data analyses.”

Commitment to Epigenomic Awareness

Epigenica AB is dedicated to providing researchers with the necessary tools to generate multiplexed, quantifiable data at high throughput and cost-efficiency, thereby fostering extensive understanding in the field of epigenomics.

Explore how EpiFinder™ GenomePro can transform your research by visiting Epigenica AB’s website at www.epigenica.se.

About Epigenica AB

Founded in Stockholm, Sweden, in 2020, Epigenica AB is a life sciences technology company at the forefront of innovation in epigenetic research. The EpiFinder platform enables researchers to conduct comprehensive epigenetic studies at unprecedented levels of speed, scalability, and cost. By leveraging proprietary and patented technology, including the high-throughput multiplex quantitative ChIP-Seq known as hmqChIP, Epigenica is poised to advance biomedical research, drug discovery, precision medicine, diagnostics, and therapies aimed at aging and longevity.